The Biostat Research and Development Center will carry out another project in collaboration with AstraZeneca. The observational study will focus on patients with generalized myasthenia gravis (gMG).

Myasthenia is a chronic autoimmune disease that leads to the weakening of skeletal muscles responsible for body movement. The main symptoms stem from impaired transmission of nerve signals to muscles, which prevents them from contracting properly.

Typical symptoms of myasthenia include muscle weakness, especially in the eyes, face, neck, and limbs, drooping eyelids (ptosis), double vision (diplopia), difficulty swallowing or speaking, and rapid muscle fatigue during repetitive activities.

What will the collaboration between Biostat and AstraZeneca on the observational study of generalized myasthenia gravis (gMG) involve?

- We will be responsible for comprehensive support, including preparing study documentation, contracting sites, monitoring, data management, providing eCRF software, full statistical support, and project management. The study is a non-interventional, multi-center project

- explains Edyta Klemba, Pharma Division Director at Biostat.

It's worth noting that this is yet another study conducted for AstraZeneca. In May this year, we reported on an observational study concerning a rare blood disease.

AstraZeneca is one of the largest biopharmaceutical companies in the world. The company has been present in Poland for over 30 years and employs 82,000 people globally, including 3,000 in Poland alone. AstraZeneca operates six R&D centers worldwide, one of which is located in Warsaw.

The Biostat Research and Development Center specializes in the comprehensive execution of observational clinical trials, supporting partners at every stage of the research process.

• More about Biostat’s services